Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2006

Innovatis, Migami, and Intertek Report Acquisitions

  • Innovatis took over the CASY brand range of automated cell counters, sizers, and analyzers, from Scharfe System. Commenting on its acquisition of the CASY brand, Ralph Martinke, Innovatis CEO, says the company is now in the position to offer customers a range of products from a single source. “We will be able to market different technologies for the automatic analysis and screening of all types of cell cultures, from animal and vegetable cells to yeast and bacteria”.

    Migami completed an asset purchase agreement with Innovay. As a result of the asset acquisition, the company's main business will become the purchase of licensing rights from U.S.- and European-based pharmaceutical and cosmetics companies; the sublicense of these rights to Asian pharmaceutical and cosmetics companies; and the distribution of such products in Asia and worldwide in the case of the cosmetic products.

    Intertek Group’s oil, chemical and agri division (Caleb Brett) acquired Alta Analytical Laboratories. Alta is a supplier of immunochemistry and LC/MS/MS bio-analytical services to the pharmaceutical and biotech industries in North America. Alta has laboratories located in San Diego and near Sacramento, CA with approximately 110 staff and counts major global pharmaceutical companies among its clients.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »